MetaCap

Gilead Sciences Earnings

NASDAQ: GILDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

166.43-0.10 (-0.06%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Gilead Sciences earnings summary

In its most recent report on Oct 29, 2026 (Sep/2026), GILD posted EPS of $2.47 versus the $2.17 consensus estimate, a positive surprise of 13.8%. Revenue for the quarter was $8.30 billion. Quarterly EPS is up 1.6% from the same quarter a year earlier.

Across the last 16 reports, GILD shares moved an average of 2.3% (in either direction) in the first trading session after results, rising 9 times and falling 7 times.

Summary generated from market data by MetaCap's automated system. Methodology

GILD earnings history

Gilead Sciences reported EPS versus estimates
Report dateEPS est.EPS actualSurprisePrice reaction
Oct 29, 2026$2.17$2.47+13.8%-2.2%
Aug 6, 2026—$-8.45—+3.9%
May 7, 2026—$1.61—-1.3%
Feb 24, 2026—$1.75—-3.4%
Nov 7, 2025—$2.43—+5.2%
Aug 7, 2025—$1.56—-0.9%
May 7, 2025—$1.04—+5.8%
Feb 28, 2025—$1.43—+2.7%
Nov 12, 2024—$1.00—+2.0%
Aug 8, 2024—$1.29—+0.2%
May 8, 2024—$-3.34—+2.7%
Feb 23, 2024—$1.14—-1.7%
Nov 7, 2023—$1.73—-0.6%
Aug 4, 2023—$0.83—+1.7%
May 3, 2023—$0.80—-2.0%
Feb 22, 2023—$1.29—+0.5%

Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.

Related